sradovich on DSK3GMQ082PROD with NOTICES

59626 Federal Register / Vol. 82, No. 240 / Friday, December 15, 2017 / Notices 

or other forms of information 

technology to minimize the information 

collection burden. 

Amy McNulty, 

Acting Director, Division of the Executive 

Secretariat. 

[FR Doc. 2017–27013 Filed 12–14–17; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Determination Concerning a Petition 

To Add a Class of Employees to the 

Special Exposure Cohort 

AGENCY: National Institute for 

Occupational Safety and Health 

(NIOSH), Centers for Disease Control 

and Prevention, Department of Health 

and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: HHS gives notice of a 

determination concerning a petition to 

add a class of employees from the 

Carborundum Company, in Niagara 

Falls, New York, to the Special 

Exposure Cohort (SEC) under the Energy 

Employees Occupational Illness 

Compensation Program Act of 2000 

(EEOICPA). 

FOR FURTHER INFORMATION CONTACT: 

Stuart L. Hinnefeld, Director, Division 

of Compensation Analysis and Support, 

National Institute for Occupational 

Safety and Health (NIOSH), 1090 

Tusculum Avenue, MS C–46, 

Cincinnati, OH 45226–1938, Telephone 

1–877–222–7570. Information requests 

can also be submitted by email to 

DCAS@CDC.GOV. 

SUPPLEMENTARY INFORMATION: 

Authority: [42 U.S.C.7384q]. 

On November 16, 2017, the Acting 

Secretary of HHS determined that the 

following class of employees does not 

meet the statutory criteria for addition 

to the SEC as authorized under 

EEOICPA: 

All employees who worked in any area of 

the Carborundum Company facility on 

Buffalo Avenue, Niagara Falls, New York, 

from January 1, 1943, through December 31, 

1976. 

John Howard, 

Director, National Institute for Occupational 

Safety and Health. 

[FR Doc. 2017–27039 Filed 12–14–17; 8:45 am] 

BILLING CODE 4163–19–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the Secretary 

Findings of Research Misconduct 

AGENCY: Office of the Secretary, HHS. 

ACTION: Notice. 

SUMMARY: Findings of research 

misconduct have been made on the part 

of Matthew Endo, former graduate 

student, Department of Chemistry, 

University of Illinois at UrbanaChampaign. The questioned research 

was supported by National Institute of 

General Medical Sciences (NIGMS), 

National Institutes of Health (NIH), 

grant R01 GM080436. The 

administrative actions, including three 

(3) years of supervision, which are 

implemented beginning on November 

16, 2017, are detailed below. 

FOR FURTHER INFORMATION CONTACT: 

Wanda K. Jones, Dr.P.H., Interim 

Director, Office of Research Integrity, 

1101 Wootton Parkway, Suite 750, 

Rockville, MD 20852, (240) 453–8200. 

SUPPLEMENTARY INFORMATION: Notice is 

hereby given that the Office of Research 

Integrity (ORI) has taken final action in 

the following case: 

Matthew Endo, University of Illinois 

at Urbana-Champaign: Based on the 

Respondent’s admission, an assessment 

conducted by University of Illinois at 

Urbana-Champaign (UIUC), and analysis 

conducted by ORI in its oversight 

review, ORI found that Mr. Matthew 

Endo, a former graduate student, 

Department of Chemistry, UIUC, 

engaged in research misconduct in 

research supported by National Institute 

of General Medical Sciences (NIGMS), 

National Institutes of Health (NIH), 

grant R01 GM080436. 

ORI found that Respondent engaged 

in research misconduct by intentionally, 

knowingly, or recklessly causing false 

data to be recorded, falsifying and/or 

fabricating data and related images by 

alteration and/or reuse and/or relabeling 

of experimental data, and reporting 

falsified and/or fabricated data in one 

(1) manuscript subsequently submitted 

for publication: 

• ‘‘Amphotericin primarily kills human 

cells by binding and extracting 

cholesterol.’’ Submitted for 

publication to the Proceedings of the 

National Academy of Sciences 

[withdrawn prior to peer review] 

(hereafter referred to as ‘‘Manuscript 

1’’) 

Specifically, ORI found that: 

• In Manuscript 1, Respondent caused 

falsified and/or fabricated results to 

be recorded by knowingly requesting 

biological testing of a mixture of 

compounds that he falsely claimed to 

be a single compound 

• In Manuscript 1, Respondent falsified 

and/or fabricated the results on page 

S26 of the Supporting Information by 

modifying the HPLC trace through 

peak erasure to make the preparation 

of C35deOAmB appear more pure 

than in the actual results of 

experimentation 

• In Manuscript 1, Respondent falsified 

and/or fabricated the results of 

Surface Plasmon Resonance data on 

page S7 of the Supporting Information 

to make the error bars smaller than 

the actual results of experimentation 

• In Manuscript 1, Respondent falsified 

and/or fabricated the results of a 

WST08 Cell Proliferation Assay on 

page S32 of the Supporting 

Information by falsely claiming to run 

the reaction in triplicate when it was 

only performed in duplicate 

• In correspondence with his advisor, 

Respondent falsified and/or fabricated 

the results of the preparation of 

putative C2deoAmB where 

Respondent modified and relabeled a 

HPLC trace and relabeled an NMR 

spectrum to falsely claim 

characterization, purity, and 

identification of sample that was sent 

for biological assay 

Mr. Endo entered into a Voluntary 

Settlement Agreement and voluntarily 

agreed for a period of three (3) years, 

beginning on November 16, 2017: 

(1) To have his research supervised; 

Respondent agreed to ensure that prior 

to the submission of an application for 

PHS support for a research project on 

which Respondent’s participation is 

proposed and prior to Respondent’s 

participation in any capacity on PHSsupported research, the institution 

employing him must submit a plan for 

supervision of Respondent’s duties to 

ORI for approval; the plan for 

supervision must be designed to ensure 

the scientific integrity of Respondent’s 

research contribution; Respondent 

agreed that he will not participate in 

any PHS-supported research until a plan 

for supervision is submitted and 

approved by ORI; 

(2) that any institution employing him 

must submit in conjunction with each 

application for PHS funds, or report, 

manuscript, or abstract involving PHS 

supported research in which 

Respondent is involved, a certification 

to ORI that the data provided by 

Respondent are based on actual 

experiments or are otherwise 

legitimately derived and that the data, 

procedures, and methodology are